Exactech, Inc. (Nasdaq: EXAC), a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, is pleased to announce the...
Exactech (Nasdaq: EXAC), a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, today announced that at a Special...
Professor Victor Valderrabano, MD, PhD, completes first global case Exactech, Inc. (Nasdaq:EXAC), a developer and producer of bone and joint restoration products for extremities, hip, and...
Merger with TPG Capital Now Valued at $737 Million Exactech, Inc. (Nasdaq: EXAC), a leading developer and producer of orthopaedic implant devices and surgical instrumentation for...
System to Debut at the AAHKS Annual Meeting, Booth #908 in Dallas Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for...
Q3 Net Income $2.9 Million; Diluted EPS $0.20 Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Exactech, Inc. - EXAC PR Newswire NEW YORK, Oct. 26, 2017 NEW YORK, Oct. 26, 2017 /PRNewswire/ -- Juan Monteverde...
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced today that, due to its...
WEISSLAW LLP: Exactech, Inc. Acquisition May Not Be in the Best Interests of EXAC Shareholders PR Newswire NEW YORK, Oct. 24, 2017 NEW YORK, Oct. 24, 2017 /PRNewswire/ -- WeissLaw LLP is...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Exactech PR Newswire NEW YORK, Oct. 24, 2017 NEW YORK, Oct. 24, 2017 /PRNewswire/ -- Rowley Law PLLC is investigating potential...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관